Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

Eriksson, Carl; Rundquist, Sara; Lykiardopoulos, Vyron; Udumyan, Ruzan; Karlén, Per; Grip, Olof; Söderman, Charlotte; Almér, Sven; Hertervig, Erik; Marsal, Jan; Gunnarsson, Jenny; Malmgren, Carolina; Delin, Jenny; Strid, Hans; Sjöberg, Mats; Öberg, David; Bergemalm, Daniel; Hjortswang, Henrik; Halfvarson, Jonas; SWIBREG SVEAH Study Group, The

doi:10.1177/17562848211023386

Public

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

Published in Therapeutic Advances in Gastroenterology • Jan 1, 2021

Authors:

Carl Eriksson

Sara Rundquist

Vyron Lykiardopoulos

Abstract

Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD). Methods: This study was a prospective, observational, multicentre study. Overall, 286 patients...

Subject

Medicine

Vedolizumab

Ulcerative colitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!